Zogenix, Inc. (NASDAQ:ZGNX) Director Mark C. Wiggins sold 6,250 shares of the stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $50.00, for a total value of $312,500.00. Following the transaction, the director now owns 6,250 shares in the company, valued at $312,500. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
NASDAQ ZGNX traded down $0.37 during trading hours on Monday, hitting $49.61. The company had a trading volume of 263,471 shares, compared to its average volume of 606,700. Zogenix, Inc. has a 52 week low of $33.43 and a 52 week high of $56.50. The company’s 50 day moving average is $47.59. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.19 and a quick ratio of 9.12. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of -15.36 and a beta of 1.92.
Zogenix (NASDAQ:ZGNX) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.06). The business had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $15.00 million. During the same quarter in the prior year, the firm posted ($0.83) earnings per share. Sell-side analysts forecast that Zogenix, Inc. will post -3.76 earnings per share for the current year.
A number of equities analysts have issued reports on the company. Mizuho increased their price target on Zogenix from $58.00 to $65.00 and gave the stock a “positive” rating in a report on Friday, June 28th. Stifel Nicolaus set a $71.00 target price on Zogenix and gave the stock a “buy” rating in a research report on Wednesday, August 7th. BidaskClub raised Zogenix from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 6th. ValuEngine raised Zogenix from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 27th. Finally, Guggenheim raised Zogenix from a “neutral” rating to a “buy” rating and upped their target price for the stock from $40.00 to $64.00 in a research report on Thursday, June 27th. One investment analyst has rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Zogenix presently has a consensus rating of “Buy” and an average target price of $63.55.
Zogenix Company Profile
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Featured Story: How Investors Can Profit from Options Trading
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.